Vaccination of Children Following Allogeneic Stem Cell Transplantation

Immunogenicity of the DTaP-IPV-HBV/Hib Combination Vaccine Infanrix Hexa and the Heptavalent Pneumococcal Conjugate Vaccine Prevenar in Pediatric Recipients of Allogeneic Haematopoietic Stem Cell Transplantation

The purpose of this study is to determine the immunogenicity and tolerability of the DTaP-IPV-HBV/Hib combination vaccine Infanrix hexa and the heptavalent pneumococcal conjugate vaccine Prevenar in pediatric recipients of allogeneic haematopoietic stem cell transplantation.

Inclusion Criteria:

• pediatric recipient of allogeneic haematopoietic stem cell transplantation
• complete remission of underlying malignant disease (if applicable)
• stable haematopoietic engraftment
• Lansky-/Karnofsky-score >= 60%

Exclusion Criteria:

• primary immunodeficiency
• hepatitis B or C, HIV infection
• application of radio-/ chemotherapy following stem cell transplantation
• extended chronic graft-versus-host disease (Karnofsky-scale < 60%)
• coagulopathy
• known allergy/hypersensitivity towards ingredients of study vaccines
• seizure disorder, progressive neurologic disease